INFUSION TECHNOLOGY, INC.'S AMBULATORY IV PUMP
This article was originally published in The Gray Sheet
INFUSION TECHNOLOGY, INC.'S AMBULATORY IV PUMP which "weighs less than one pound and is the size of a personal walkman stereo," according to the company, is scheduled for limited release to hospitals in November or December. Bolstered by a network of independent specialty distributors, ITI plans to move into the home health care market in early 1994. The pump has FDA 510(k) premarket clearance. Emphasizing the device's versatility in administering an assortment of medications under different conditions, ITI says the pump can be used "for multiple infusion therapies including pain management, chemotherapy, antibiotic therapy and TPN (total parenteral nutrition)." ITI acquired the pump, along with related patents and technologies, from Pfizer subsidiary Strato Medical. Pfizer acquired Strato in 1990. Known as "pumpman" at Strato (ITI has not yet unveiled its name for the device), the ambulatory intravenous infusion pump is the second product ITI has obtained from Strato. The first device, the Stratofuse PCA patient controlled analgesia pump and ambulatory infuser for programmable, multi-drug therapy, was acquired in 1992 and marked ITI's entry into the pain management arena. Stratoftise was launched by Strato in 1987, and marketed under an exclusive distribution agreement with Baxter between 1988 and 1992 when ITI assumed exclusive marketing rights. Citing Frost and Sullivan estimates, ITI says the ambulatory pump market is expected to exceed 20,000 units and $60 mil. in industry sales in 1993. The market has been growing 20% each year since 1988. Following completion of upgrades to the Stratofuse infuser, including increased programming capability and printer improvements, ITI is planning to market the Stratofuse PCA 11 "shortly," according to the company. Also slated for market introduction is an infusion device based on the principles of chronotherapy, "a treatment that schedules drug dosing according to the daily biological rhythms of the patient." According to ITI, "chronobiologic investigations have shown that the therapeutic effect and toxicity of drugs varies greatly with an individual's circadian cycle." Farther down the pike is a syringe infusion device geared for use by anesthesiologists in the operating room. ITI was founded in 1992 by two former Strato vice presidents and Robert Miller and Paul Fenton. Miller is president of ITI; Fenton oversees research and development. The company is located in Danvers, Massachusetts.
Sign in to continue reading.
New to Medtech Insight?
Start a free trial today!
Register for our free email digests: